Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Actuate Therapeutics, Inc. on May 21, 2026. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Fort Worth, Texas. The filing details the outcomes of shareholder votes regarding board elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results rather than financial performance data.
Material Changes and Voting Results
The following material actions were taken by stockholders at the Annual Meeting:
- Director Elections: Stockholders elected two Class II director nominees to serve three-year terms until the 2029 Annual Meeting:
- Aaron G.L. Fletcher, Ph.D.: Received 14,877,247 votes "For," 1,883,025 "Withheld," and 1,871,309 Broker Non-Votes.
- Jason Keyes: Received 16,727,875 votes "For," 32,397 "Withheld," and 1,871,309 Broker Non-Votes.
- Auditor Ratification: Stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 18,571,817
- Votes Against: 50,023
- Abstain: 9,741
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the voting results.
Key Facts for Investor Verification
- Confirm the tenure of the newly elected directors (Aaron G.L. Fletcher and Jason Keyes) extends through the 2029 Annual Meeting.
- Verify the appointment of Crowe LLP as the independent auditor for the fiscal year ending December 31, 2026.
- Note the significant number of Broker Non-Votes (1,871,309) recorded for the director elections, which may indicate shares held in street name where brokers lacked discretionary voting authority.
- Review subsequent filings (e.g., 10-K or 10-Q) for financial metrics, as this 8-K contains no financial data.